• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.6
• /
• pp.2395-2403
• /
• 2014

As the recurrence and mortality rates of bladder cancer are high, research is needed to find suitable biomarkers for early detection, evaluation of prognosis, and surveillance of drug responses. We performed a computerized search of the Medline/PubMed databases with the key words bladder cancer, biomarker, early detection, prognosis and drug response. Several markers were identified at DNA, RNA and protein levels with different sensitivities and specificities. Only a few of the potential bladder cancer biomarkers have been approved for clinical use. Efforts now should be concentrated on finding a panel of markers with acceptable sensitivity and specificity for early detection of bladder cancer.

• Asian Pacific Journal of Cancer Prevention
• /
• v.13 no.5
• /
• pp.2285-2289
• /
• 2012

Multidrug resistance (MDR) is a main cause of failure in the chemotherapeutic treatment of malignant disorders. One of the well-known genes responsible for drug resistance encodes the multidrug resistance-associated protein (MRP1). The association of MRP1 with clinical drug resistance has not systematically been investigated in Iranian pediatric leukemia patients. We therefore applied real-time RT-PCR technology to study the association between the MRP1 gene and MDR phenotype in Iranian pediatric leukemia patients. We found that overexpression of MRP1 occurred in most Iranian pediatric leukemia patients at relapse. However, no relation between MRP1 mRNA levels and other clinical characteristics, including cytogenetic subgroups and FAB subtypes, was found.

• Journal of Korean Public Health Nursing
• /
• v.16 no.2
• /
• pp.400-411
• /
• 2002

This study was performed to identify the drug use and reuse relating characteristics and reuse relating factors in illegal drug users. Subjects consisted of 88 illegal drug users. Some of them were confined in a mental hospital or National Forensic Psychiatric Hospital located in Chung-nam province, others on attending a drug abuse prevention program in Seoul Probational Institute. Data were collected during the period from February 1, 2002 to February 25, 2002, and analyzed by SAS program. version 6.12. for Wilcoxon rank sum test, Pearson Correlation, Multiple regression. Results were as follows; 1. Drug use characteristics were as follows. $19.3\%$ was has drug family history and $20.7\%$ was has alcohol family history. Main drug was Phillopon$44.3\%$, inhalants $35.2\%$, LSD et al $22.7\%$. Drug use rate of months was everyday $31.2\%$, every other day $24.4\%$. 2. $100\%$ has experienced abstinence and reuse. Abstinence period was less than 12 months in $49.4\%$ and reuse period was less than 6 months in $58.6\%$. 3. Drug use and reuse characteristics related to general characteristics was identified as below. Abstinence period of male was longer than that of female. Person who have drug family history experienced more drugs and person who have family alcohol history started earlier. 4. Reuse periods was correlated with abstinence periods, age. And abstinence period was correlated with age and outcome that following reuse. 5. The multiple regression was used to identify the relating factors that influence reuse period and abstinence period. At the state of controlling abstinence period. inhalants users have 10.07 days shorter reuse period than others. And abstinence period had lengthened age, bad health status, early initiate age, and long reuse period.

• Journal of Korean Academy of Nursing
• /
• v.42 no.4
• /
• pp.568-578
• /
• 2012

Purpose: The purpose of this cross-sectional study was to examine current status of IT-based medication error prevention system construction and the relationships among system construction, medication error management climate and perception for system use. Methods: The participants were 124 patient safety chief managers working for 124 hospitals with over 300 beds in Korea. The characteristics of the participants, construction status and perception of systems (electric pharmacopoeia, electric drug dosage calculation system, computer-based patient safety reporting and bar-code system) and medication error management climate were measured in this study. The data were collected between June and August 2011. Descriptive statistics, partial Pearson correlation and MANCOVA were used for data analysis. Results: Electric pharmacopoeia were constructed in 67.7% of participating hospitals, computer-based patient safety reporting systems were constructed in 50.8%, electric drug dosage calculation systems were in use in 32.3%. Bar-code systems showed up the lowest construction rate at 16.1% of Korean hospitals. Higher rates of construction of IT-based medication error prevention systems resulted in greater safety and a more positive error management climate prevailed. Conclusion: The supportive strategies for improving perception for use of IT-based systems would add to system construction, and positive error management climate would be more easily promoted.

• Biomolecules & Therapeutics
• /
• v.20 no.3
• /
• pp.268-272
• /
• 2012

Nephrotoxicity occurs when kidney-specific detoxification and excretion do not work properly due to the damage or destruction of kidney function by exogenous or endogenous toxicants. Exposure to drugs often results in toxicity in kidney which represents the major control system maintaining homeostasis of body and thus is especially susceptible to xenobiotics. Understanding the toxic mechanisms for nephrotoxicity provides useful information on the development of drugs with therapeutic benefits with reduced side effects. Mechanisms for drug-induced nephrotoxicity include changes in glomerular hemodynamics, tubular cell toxicity, inflammation, crystal nephropathy, rhabdomyolysis, and thrombotic microangiopathy. Biomarkers have been identified for the assessment of nephrotoxicity. The discovery and development of novel biomarkers that can diagnose kidney damage earlier and more accurately are needed for effective prevention of drug-induced nephrotoxicity. Although some of them fail to confer specificity and sensitivity, several promising candidates of biomarkers were recently proved for assessment of nephrotoxicity. In this review, we summarize mechanisms of drug-induced nephrotoxicity and present the list of drugs that cause nephrotoxicity and biomarkers that can be used for early assessment of nephrotoxicity.

• Journal of Digestive Cancer Reports
• /
• v.8 no.2
• /
• pp.97-101
• /
• 2020

Metformin is a widely used first-line anti-diabetic drug worldwide. Epidemiologic studies using the large population-based cohort database have shown the association between metformin uses and reduced risk of various type cancers including gastric cancer. In the gastric cancer prevention, metformin use was associated with the significant reduction of gastric cancer risk, especially for long-term metformin users. However, there is no well-designed randomized controlled clinical trial investigating the effect of metformin as a chemopreventive drug for gastric cancer. Therefore, further well-designed clinical trials will be needed to implement metformin for chemoprevention of gastric cancer.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 2006.04a
• /
• pp.109-120
• /
• 2006

Alzheimer's disease (AD) is an age-related neurodegenerative disorder. The pathological hallmarks of AD are senile plaques and neurofibrillary tangles in the brain. Major component of senile plaques is amyloid beta peptide(A$\beta$) which is derived from amyloid precursor protein (APP). A$\beta$ is generated through the sequential cleavage of App by $\beta$ - and $\gamma$-secretases. $\beta$-secretase excises the ectodomain of APP ($\beta$-APPs) to leave a 99-amino acid long C-terminal fragment (APP-C99-CTF) in the membrane. $\gamma$-secretase then cleaves this membrane-tethered APP-CTF within the transmembrane domain, so releasing A$\beta$ peptides and APP-intracellular domain (AICD). Thus, $\beta$- and $\gamma$-secretase are regarded to perform the key steps in the pathogenesis of AD and have become important therapeutic targets in the prevention and treatment of AD. Enormous efforts have been focused to develop the amyloid beta related drug for cure of AD becuase A$\beta$ is believed to be one of the major causes of AD. since major pharmaceutical companies in world wide base compete to develop new drug for AD, we have to be careful to choose the drug target to success the tough race. In the present talk, possible drug targets based on basic research results will be discussed. These molecules should be a good target for development of new drug for AD and be less competitive to have a good shape for world wide competition.

• Korean Journal of Veterinary Service
• /
• v.17 no.1
• /
• pp.44-53
• /
• 1994

The result that investigated aberage weekly oocyst nymbers in faeces from 16 broiler farms, Oocyst can be found in the highest during the 5 weeks age. The 3 of the 16 farms have clinical sign of the coccidiosis at the faeces collection. Anticoccidial drug sensitivity against Oocyst isolated in 2 farms to have clinical coccidiosis was tested for the drug susceptibility and resistance in order to prevention coccidiosis effectively. Maduramicin, Salynomicif Narasin Lasalocid, Monensin, Robenidine and Dicrazulir were used an anticoccidial drugs. The results ; Anticoccidial index(ACI) of the A farm were 201.50 in a chicken group treated with Dicrazulir, 194.84 with Robenidine. 172.79 with Maduramicin 6ppm 170.49 with Salynomicin, 168.02 with maduramicin 5ppm 165.77 with Lasalocid, 143.34 with Monensin and 140.63 with Narasin. ACI of the B farm were 193.40 in a chicken group treated Robenidine, 190.64 with Dicrazuril, 158.75 with Maduramic in 6ppm, 151.62 with Maduramicin 5ppm, 149.44 with Salynomicin, 143.10 with lasalocid, 138.11 with Monensin and 137.50 with Narasin. According to interpretation of ACI from Kawasae et al, the drug resistance(less than 120 of ACI) not appeared in two farms, vut the drug tolerance(120-160 of ACI) appeared in two group treated with Monesin and Nalacin in csae of A farm and in all group with treated anticoccidial drug in case of B farm.

• Journal of Korean Academy of Nursing
• /
• v.29 no.3
• /
• pp.656-664
• /
• 1999

Accidents are the leading cause of death in children worldwide. The purpose of this study is to use basic data of safety education, counseling, and information available regarding accident prevention to examine the degree of mothers' accident prevention practices for their children. Data were collected from June to October, 1998 from 587 mothers including 2 University hospitals located in Seoul and Kyoungki-Do. By using the 30 item questionnaire, which was created by researchers through literature review, the degree of mothers' accident prevention practices for their children was measured. The degree of accident prevention practices of mothers shown ranged 70-118 and averaged 3.19. Compared to the composit area average score, drug keeping had the highest score of 3.57 The next highest scores and traffic safety(3.41), and supervision of child(3.30). Prevention against burning was the lowest point at 2.58. With the respect to the demographic characteristics, there were stastically significant differences in the mothers' education(F＝4.291, p＝.014), type of residence(F＝3.979, p＝.008), and child developmental age (F＝5.275, p＝.001). The degree of accident prevention practices of mothers were relatively high. But the area which showed the low degree of accident prevention practices, required nurses' active education, counseling, social interest and support, and mass media participation.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.4
• /
• pp.2159-2165
• /
• 2013

Cancer registries help to establish and maintain cancer incidence reporting system, serve as a resource for investigation of cancer and its causes, and provide information for planning and evaluation of preventive and control programs. However, their wider role in directly enhancing oncology drug access has not been fully explored. We examined the value of cancer registries in oncology drug access in the Asia-Pacific region on three levels: (1) specific registry variable types; (2) macroscopic strategies on the national level; and (3) a regional cancer registry network. Using literature search and proceedings from an expert forum, this paper covers recent cancer registry developments in eight economies in the Asia-Pacific region - Australia, China, Hong Kong, Malaysia, Singapore, South Korea, Taiwan, and Thailand - and the ways they can contribute to oncology drug access. Specific registry variables relating to demographics, tumor characteristics, initial treatment plans, prognostic markers, risk factors, and mortality help to anticipate drug needs, identify high-priority research area and design access programs. On a national level, linking registry data with clinical, drug safety, financial, or drug utilization databases allows analyses of associations between utilization and outcomes. Concurrent efforts should also be channeled into developing and implementing data integrity and stewardship policies, and providing clear avenues to make data available. Less mature registry systems can employ modeling techniques and ad-hoc surveys while increasing coverage. Beyond local settings, a cancer registry network for the Asia-Pacific region would offer cross-learning and research opportunities that can exert leverage through the experiences and capabilities of a highly diverse region.